{
    "response": "**Overall Treatment Decision:** Yes\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days (or oral equivalent 500\u20131250 mg)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Acute disabling relapse with optic/cerebellar signs Improves speed of recovery Vitals stable and no sepsis features; infection screen to proceed in parallel\n\n*   **Treatment:** Proton pump inhibitor while on high-dose steroids\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** GI protection during pulse steroids Reduces risk of steroid-induced gastritis/ulcer\n\n*   **Treatment:** Physiotherapy and occupational therapy\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Gait ataxia and left-leg spasticity causing functional impairment Prevents deconditioning and falls\n\n*   **Treatment:** Baclofen for spasticity (titrate)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Objective left lower-limb spasticity with clonus Improves mobility and comfort\n\n*   **Treatment:** Plasma exchange (5\u20137 exchanges) if steroid-refractory\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Second-line for severe relapse not improving within 2 weeks More invasive therapy reserved for nonresponse\n\n*   **Treatment:** Initiate high-efficacy disease-modifying therapy (e.g., ocrelizumab or natalizumab depending on JCV status)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Start after diagnostic confirmation and baseline screening Vaccination optimisation and risk stratification required\n\n*   **Treatment:** Vaccination updates (VZV, influenza, COVID-19, HBV as indicated)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Reduce infection risk before immunotherapy Live vaccines contraindicated after immunosuppression\n\n*   **Treatment:** Vitamin D supplementation (e.g., cholecalciferol 1000\u20132000 IU daily)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Low vitamin D is associated with MS activity Safe and may reduce relapse risk\n\n\ntreatments = [{\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days (or oral equivalent 500\\u20131250 mg)\", \"timing\": \"Start Now\", \"reasons\": [\"Acute disabling relapse with optic/cerebellar signs\", \"Improves speed of recovery\", \"Vitals stable and no sepsis features; infection screen to proceed in parallel\"]}, {\"treatment\": \"Proton pump inhibitor while on high-dose steroids\", \"timing\": \"Start Now\", \"reasons\": [\"GI protection during pulse steroids\", \"Reduces risk of steroid-induced gastritis/ulcer\"]}, {\"treatment\": \"Physiotherapy and occupational therapy\", \"timing\": \"Start Now\", \"reasons\": [\"Gait ataxia and left-leg spasticity causing functional impairment\", \"Prevents deconditioning and falls\"]}, {\"treatment\": \"Baclofen for spasticity (titrate)\", \"timing\": \"Start Now\", \"reasons\": [\"Objective left lower-limb spasticity with clonus\", \"Improves mobility and comfort\"]}, {\"treatment\": \"Plasma exchange (5\\u20137 exchanges) if steroid-refractory\", \"timing\": \"Delay\", \"reasons\": [\"Second-line for severe relapse not improving within 2 weeks\", \"More invasive therapy reserved for nonresponse\"]}, {\"treatment\": \"Initiate high-efficacy disease-modifying therapy (e.g., ocrelizumab or natalizumab depending on JCV status)\", \"timing\": \"Delay\", \"reasons\": [\"Start after diagnostic confirmation and baseline screening\", \"Vaccination optimisation and risk stratification required\"]}, {\"treatment\": \"Vaccination updates (VZV, influenza, COVID-19, HBV as indicated)\", \"timing\": \"Delay\", \"reasons\": [\"Reduce infection risk before immunotherapy\", \"Live vaccines contraindicated after immunosuppression\"]}, {\"treatment\": \"Vitamin D supplementation (e.g., cholecalciferol 1000\\u20132000 IU daily)\", \"timing\": \"Start Now\", \"reasons\": [\"Low vitamin D is associated with MS activity\", \"Safe and may reduce relapse risk\"]}]"
}